Advertisement

Optic Neuritis

  • Neil R. Miller
Chapter

Abstract

Optic neuritis may be caused by a variety of infectious, demyelinating, and inflammatory disorders. Following an attack of acute demyelinating optic neuritis (ON), there is a risk of developing multiple sclerosis (MS) especially if one or more periventricular demyelinating white-matter lesions is seen on magnetic resonance imaging (MRI) of the brain. Early treatment of MS with immunomodulatory drugs may helpful after ON. Other inflammatory demyelination syndromes such as neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD) or myelin oligodendrocyte glycoprotein (MOG) syndrome may mimic MS and can present with acute optic neuritis. In contrast to MS related ON however, bilateral, anterior, and/or recurrent ON is more likely to occur in NMO or MOG syndromes.

Keywords

Neuromyelitis optica Myelin oligodendrocyte glycoprotein Optic neuritis 

References

  1. 1.
    Smith CH. Optic neuritis. In: Miller NR, Newman NJ, Biousse V, Kerrison JB, editors. Walsh and Hoyt’s clinical neuro-ophthalmology, vol. 1. 6th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2005. p. 293–348.Google Scholar
  2. 2.
    Parmley VC, Schiffman JS, Maitland CG, et al. Does neuroretinitis rule out multiple sclerosis? Arch Neurol. 1987;44:1045–8.CrossRefGoogle Scholar
  3. 3.
    Gould H, Kaufman HE. Sarcoid of the fundus. Arch Ophthalmol. 1961;65:453–6.CrossRefGoogle Scholar
  4. 4.
    Hart WM Jr, Burde RM. Optic disk edema in sarcoidosis. Am J Ophthalmol. 1979;88:769–71.CrossRefGoogle Scholar
  5. 5.
    Spalton DJ, Sanders MD. Fundus changes in histologically confirmed sarcoidosis. Br J Ophthalmol. 1981;65:348–58.CrossRefGoogle Scholar
  6. 6.
    Beardsley TL, Brown SVL, Sydnor CF, et al. Eleven cases of sarcoidosis of the optic nerve. Am J Ophthalmol. 1984;97:62–77.CrossRefGoogle Scholar
  7. 7.
    Graham EM, Ellis CJK, Sanders MD, et al. Optic neuropathy in sarcoidosis. J Neurol Neurosurg Psychiatry. 1986;49:756–63.CrossRefGoogle Scholar
  8. 8.
    Optic Neuritis Study Group. The clinical profile of acute optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1991;109:1673–8.CrossRefGoogle Scholar
  9. 9.
    McDonald WI, Barnes D. The ocular manifestations of multiple sclerosis. 1. Abnormalities of the afferent visual system. J Neurol Neurosurg Psychiatry. 1992;55:747–52.CrossRefGoogle Scholar
  10. 10.
    Page NGR, Bolger JP, Sanders MD. Auditory evoked phosphenes in optic nerve disease. J Neurol Neurosurg Psychiatry. 1982;45:7–12.CrossRefGoogle Scholar
  11. 11.
    Ménage MJ, Papakostopoulos D, Hart JCD, et al. The Farnsworth-Munsell 100 hue test in the first episode of demyelinating optic neuritis. Br J Ophthalmol. 1993;77:68–74.CrossRefGoogle Scholar
  12. 12.
    Keltner JL, Johnson CA, Spurr JO, et al. Baseline visual field profile of optic neuritis: the experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1993;111:231–4.CrossRefGoogle Scholar
  13. 13.
    Beck RW, Cleary PA, Backlund JC, et al. The course of visual recovery after optic neuritis: experience of the Optic Neuritis Treatment Trial. Ophthalmology. 1994;101:1771–8.CrossRefGoogle Scholar
  14. 14.
    Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med. 1992;326:581–8.CrossRefGoogle Scholar
  15. 15.
    Beck RW. Optic Neuritis Study Group: the Optic Neuritis Treatment Trial: implications for clinical practice. Arch Ophthalmol. 1992;110:331–2.CrossRefGoogle Scholar
  16. 16.
    Keltner JL, Johnson CA, Spurr JO, et al. Visual field profile of optic neuritis: one-year follow-up in the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1994;112:946–53.CrossRefGoogle Scholar
  17. 17.
    Optic Neuritis Study Group. Visual function more than 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Am J Ophthalmol. 2004;137:77–83.CrossRefGoogle Scholar
  18. 18.
    Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology. 2008;115:1079–82.Google Scholar
  19. 19.
    Beck RW, Kupersmith MJ, Cleary PA, et al. Fellow eye abnormalities in acute unilateral optic neuritis: experience of the Optic Neuritis Treatment Trial. Ophthalmology. 1993;100:691–8.CrossRefGoogle Scholar
  20. 20.
    Morrow SA, Fraser JA, Day C, et al. Effect of treating acute optic neuritis with bioequivalent oral vs. intravenous corticosteroids: A randomized clinical trial. JAMA Neurol. 2018;75:690–6.CrossRefGoogle Scholar
  21. 21.
    Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000;343:898–904.CrossRefGoogle Scholar
  22. 22.
    Comi G, Filippi E, Barkhoff F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet. 2001;357:1576–82.CrossRefGoogle Scholar
  23. 23.
    Optic Neuritis Study Group. The five year risk of multiple sclerosis after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Neurology. 1997;49:1404–13.CrossRefGoogle Scholar
  24. 24.
    Optic Neuritis Study Group. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis. Arch Ophthalmol. 2003;121:944–9.CrossRefGoogle Scholar
  25. 25.
    Miller DH, Khan OA, Sheremata W, et al. A controlled trial of natalizumab for multiple sclerosis. N Engl J Med. 2003;348:15–23.CrossRefGoogle Scholar
  26. 26.
    Petzold A, Pittock S, Lennon V, et al. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune-mediated optic neuritis. J Neurol Neurosurg Psychiatry. 2010;81:109–11.CrossRefGoogle Scholar
  27. 27.
    Jarius S, Frederikson J, Waters P, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci. 2010;298:158–62.CrossRefGoogle Scholar
  28. 28.
    Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol. 2014;13:83–9.CrossRefGoogle Scholar
  29. 29.
    Chen JJ, Tobin WO, Majed M, et al. Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the Optic Neuritis Treatment Trial. JAMA Ophthalmol. 2018;136:419–22.CrossRefGoogle Scholar
  30. 30.
    Levin MH, Bennett JL, Verkman AS. Optic neuritis in neuromyelitis optica. Prog Retin Eye Res. 2013;36:159–71.CrossRefGoogle Scholar
  31. 31.
    Baghbanian SM, Asgari N, Sahraian MA, Modhadasi AN. A comparison of pediatric and adult neuromyelitis optica spectrum disorders: a review of clinical manifestations, diagnosis, and treatment. J Neurol Sci. 2018;388:222–31.CrossRefGoogle Scholar
  32. 32.
    Geraldes R, Ciccarelli O, Barkhof F, et al. The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nat Rev Neurol. 2018;14:199–213. [Epub 9 Mar 2018].CrossRefGoogle Scholar
  33. 33.
    Chee CG, Park KS, Lee JW, et al. MRI features of aquaporin-4 antibody-positive longitudinally extensive transverse myelitis: insights into the diagnosis of neuromyelitis optica spectrum disorders. AJNR Am J Neuroradiol. 2018;39:782–7.CrossRefGoogle Scholar
  34. 34.
    Mandler RN, Ahmed W, Dencoff JE. Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998;51:1219–20.CrossRefGoogle Scholar
  35. 35.
    Costanzi C, Matiello M, Luchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011;77:659–66.CrossRefGoogle Scholar
  36. 36.
    Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, et al. Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol. 2010;67:1131–6.CrossRefGoogle Scholar
  37. 37.
    Stellmann J-P, Krumbholz M, Friede T, et al. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. J Neurol Neurosurg Psychiatry. 2017;88:639–47.CrossRefGoogle Scholar
  38. 38.
    Kitley J, Elsone L, George J, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry. 2013;84:918–21.CrossRefGoogle Scholar
  39. 39.
    Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica. Multicenter study of treatment efficacy. JAMA Neurol. 2014;71:324–30.CrossRefGoogle Scholar
  40. 40.
    Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17:1019–32.CrossRefGoogle Scholar
  41. 41.
    Palace J, Leite MI, Jacob A. A practical guide to the treatment of neuromyelitis optica. Pract Neurol. 2012;12:209–14.CrossRefGoogle Scholar
  42. 42.
    Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12:554–62.CrossRefGoogle Scholar
  43. 43.
    Cabre P, Olindo S, Marignier R, et al. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry. 2013;84:511–6.CrossRefGoogle Scholar
  44. 44.
    Bichuetti DB, Oliveira EM, Boulos FC, et al. Lack of response to pulse cyclophosphamide in neuromyelitis optica; evaluation of 7 patients. Arch Neurol. 2012;69:938–9.CrossRefGoogle Scholar
  45. 45.
    Khatri BO, Kramer J, Dukic M, et al. Maintenance plasma exchange therapy for steroid-refractive neuromyelitis optica. J Clin Apher. 2012;27:183–92.CrossRefGoogle Scholar
  46. 46.
    Merle H, Olindo S, Jeannin S, et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol. 2012;130:858–62.CrossRefGoogle Scholar
  47. 47.
    Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: evaluation of 872 attacks and 1,153 treatment courses. Ann Neurol. 2016;79:206–16.CrossRefGoogle Scholar
  48. 48.
    Kageyama T, Komori M, Miyamoto K, et al. Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol. 2013;260:627–34.CrossRefGoogle Scholar
  49. 49.
    Wingerchuk DM. Neuromyelitis optica: potential roles for intravenous immunoglobulins. J Clin Immunol. 2013;33(Suppl 1):S33–7.CrossRefGoogle Scholar
  50. 50.
    Kieseier BC, Stuve O, Dehmel T, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol. 2013;70:390–3.CrossRefGoogle Scholar
  51. 51.
    Palace J, Leite MI, Nairne A, et al. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol. 2010;67:1016–7.CrossRefGoogle Scholar
  52. 52.
    Kim SH, Kim W, Li XF, et al. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler. 2012;18:1480–3.CrossRefGoogle Scholar
  53. 53.
    Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012;18:113–5.CrossRefGoogle Scholar
  54. 54.
    Barnett MH, Prineas JW, Buckland ME, et al. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler. 2012;18:1480–3.CrossRefGoogle Scholar
  55. 55.
    Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012;69:239–45.CrossRefGoogle Scholar
  56. 56.
    Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140:3128–38.CrossRefGoogle Scholar
  57. 57.
    Matsuda R, Kezuka T, Umazume A, et al. Clinical profile of anti-myelin oligodendrocyte glycoprotein antibody seropositive cases of optic neuritis. Neuro-Ophthalmology. 2015;39:213–9.CrossRefGoogle Scholar
  58. 58.
    Chen JJ, Flanagan EP, Jitprapaikulsan J, et al. Myelin oligodencrocyte glycoprotein antibody (MOG-IgG)-positive optic neuritis: clinical characteristics, radiologic clues and outcome. Presented at the annual meeting of the North American Neuro-Ophthalmology Society, Hawaii, 7 Mar 2018.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Wilmer Eye Institute, Johns Hopkins HospitalBaltimoreUSA

Personalised recommendations